Consumer advocacy group Public Citizen slammed the FDA for not disclosing the name of the drug in shortage due to the coronavirus outbreak.
The FDA said Feb. 27 that the U.S. is experiencing its first drug shortage related to the coronavirus outbreak, but didn’t disclose the name of the affected drug or the drugmaker. The agency told Becker’s Hospital Review the information is considered « confidential commercial information » and that drugmakers aren’t legally required to provide detailed information.
In a letter to FDA Commissioner Stephen Hahn, MD, dated March 3, Public Citizen wrote that it is « dismayed by the refusal of the FDA to identify the medication. »
It argued that the name of the drug shouldn’t be considered confidential commercial information because it isn’t reasonable to expect it would cause substantial competitive harm and because publicly traded pharmaceutical companies already have to disclose that information to their shareholders…